Mga Batayang Estadistika
| LEI | 549300L6Q02MAX72BH35 |
| CIK | 1779020 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Danimer Scientific, Inc. - Equity Warrant
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| March 18, 2025 |
V&E Draft 3.17.25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorpor |
|
| February 28, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2025 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 17, 2025 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange ("NYSE" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Class A common stock (the "Common Stock), of Danimer Scientific, Inc. |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 31, 2024 |
Danimer Scientific Announces Common Stock Expected to Begin Trading Promptly on OTCQX Marketplace –Dividend warrants continue to trade on OTCQX marketplace under “DNMRW”– BAINBRIDGE, GA – December 31, 2024 – Danimer Scientific, Inc. |
|
| December 31, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 54 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 810,899 Shares of Common Stock Up to 406,981 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to time, |
|
| December 17, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 53 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 810,899 Shares of Common Stock Up to 406,981 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to time, |
|
| December 17, 2024 |
Danimer Scientific Takes Action to Strengthen Capital Structure –Announces Issuance of $11,250,000 Super Senior Secured Promissory Note BAINBRIDGE, GA – December 17, 2024 – Danimer Scientific, Inc. |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 13, 2024 |
December [], 2024 [Name] Via E-Mail Retention Bonus Agreement Dear [Name]: On behalf of Danimer Scientific, Inc. |
|
| December 13, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 51 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 810,899 Shares of Common Stock Up to 406,981 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to time, |
|
| December 13, 2024 |
424B3 1 retention8-k-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 52 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 810,899 Shares of Common Stock Up to 406,981 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as suppl |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 09, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 3, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 50 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 810,899 Shares of Common Stock Up to 406,981 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to time, |
|
| November 19, 2024 |
Third Quarter 2024 Earnings Presentation November 19, 2024 Third Quarter 2024 Earnings Presentation November 19, 2024 This presentation (“Presentation”) is for informational purposes only. |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 19, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 49 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 810,899 Shares of Common Stock Up to 406,981 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to time, |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| November 19, 2024 |
Danimer Scientific Announces Third Quarter 2024 Results -Additional Resin Orders and Deliveries Continue to Support 20-Million Pound Cutlery Award –- - 100% Compostable Skittles® Bag Made with Nodax® PHA Featured at NFL Game - BAINBRIDGE, GA – November 19, 2024 – Danimer Scientific, Inc. |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P |
|
| November 14, 2024 |
DNMR / Danimer Scientific, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-dnmr093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DANIMER SCIENTIFIC, INC. (Name of Issuer) Class A Common stock, $0.0001 par value per share (Title of Class of Securities) 236272100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 13, 2024 |
Sixth Amended and Restated Certificate of Incorporation of Danimer Scientific, Inc. SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DANIMER SCIENTIFIC, INC. |
|
| November 13, 2024 |
424B3 1 6thamendmentcoi-424b.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 48 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 810,899 Shares of Common Stock Up to 406,981 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as sup |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 24, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 47 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| October 24, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 18, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 46 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [x] Definitive Proxy |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [x] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy |
|
| August 8, 2024 |
DANIMER SCIENTIFIC, INC. 2020 LONG-TERM INCENTIVE PLAN STOCK APPRECIATION RIGHTS AGREEMENT DANIMER SCIENTIFIC, INC. 2020 LONG-TERM INCENTIVE PLAN STOCK APPRECIATION RIGHTS AGREEMENT Danimer Scientific, Inc. (the “Company”) has granted the Participant (named in Section 1 hereof) the number of stock appreciation rights (the “Award”) set forth in Section 1 (each, a “SAR” and collectively, the “SARs”) under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the “Plan”). Each SAR en |
|
| August 8, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 45 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 8, 2024 |
Danimer Scientific Announces Second Quarter 2024 Results -Additional Resin Orders to Support 20-Million Pound Cutlery Award –- - Company Forecasting Annualized PHA Revenues to More Than Triple by End of Q2 2025 - - Pro-Rata Warrant Dividend Transaction Provides Balance Sheet Deleveraging Opportunity - BAINBRIDGE, GA – August 8, 2024 – Danimer Scientific, Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| August 8, 2024 |
Second Quarter 2024 Earnings Presentation August 8, 2024 Second Quarter 2024 Earnings Presentation August 8, 2024 This presentation (“Presentation”) is for informational purposes only. |
|
| July 12, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 44 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| July 12, 2024 |
EXHIBIT 4.1 WARRANT AGREEMENT Dated as of July , 2024 between DANIMER SCIENTIFIC, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY as Warrant Agent Warrants for Shares of Common Stock of Danimer Scientific, Inc. TABLE OF CONTENTS Page Article I Definitions Section 1.01 Definitions 1 Section 1.02 Other Definitions 5 Section 1.03 Rules of Construction. Unless the text or context otherwise require |
|
| July 12, 2024 |
Danimer Scientific, Inc. Up to 70,134,322 Shares of Common Stock Filed pursuant to Rule 424(b)(2) Registration No. 333-279371 PROSPECTUS SUPPLEMENT (to Prospectus dated June 5, 2024) Danimer Scientific, Inc. Up to 70,134,322 Shares of Common Stock This prospectus supplement and the accompanying prospectus relate to the issuance and sale of up to an aggregate of 70,134,322 shares of Class A common stock, $0.0001 par value per share (“Common Stock”) of Danimer Sc |
|
| July 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(2) (Form Type) DANIMER SCIENTIFIC, INC. |
|
| July 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(2) (Form Type) DANIMER SCIENTIFIC, INC. |
|
| July 12, 2024 |
Danimer Scientific, Inc. Up To 5,939,560 Shares of Common Stock Filed pursuant to Rule 424(b)(2) Registration No. 333-279371 PROSPECTUS SUPPLEMENT (to Prospectus dated June 5, 2024) Danimer Scientific, Inc. Up To 5,939,560 Shares of Common Stock Danimer Scientific, Inc. (the “Company,” “Danimer,” “we,” “our,” or “us”) is offering up to 5,939,560 shares of its Class A common stock, $0.0001 par value per share (“Common Stock”) directly to B. Dyson Capital Adviso |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 12, 2024 |
EXHIBIT 4.1 WARRANT AGREEMENT Dated as of July 12, 2024 between DANIMER SCIENTIFIC, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY as Warrant Agent Warrants for Shares of Common Stock of Danimer Scientific, Inc. TABLE OF CONTENTS Page Article I Definitions Section 1.01 Definitions 1 Section 1.02 Other Definitions 5 Section 1.03 Rules of Construction. Unless the text or context otherwise requi |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Danimer Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1924518 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 140 Industrial B |
|
| July 11, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 43 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| July 10, 2024 |
Fifth Amended and Restated Certificate of Incorporation. FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DANIMER SCIENTIFIC, INC. |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 09, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 8, 2024 |
DNMR / Danimer Scientific, Inc. / BlackRock Inc. Passive Investment us2362721001070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) DANIMER SCIENTIFIC, INC. - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 236272100 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy |
|
| June 3, 2024 |
DANIMER SCIENTIFIC, INC. 140 Industrial Boulevard, Bainbridge, GA 39817 (229) 243-7075 DANIMER SCIENTIFIC, INC. 140 Industrial Boulevard, Bainbridge, GA 39817 (229) 243-7075 June 3, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Danimer Scientific, Inc. Registration Statement on Form S-3 Filed: May 13, 2024 File No.: 333-279371 Acceleration Request Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [x] Definitive Proxy |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy |
|
| May 24, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 42 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 24, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 41 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 20, 2024 |
Exhibit 10.1 TRANSITION AND RETIREMENT AGREEMENT This Transition and Retirement Agreement (this “Agreement”), dated as of May 20, 2024 (the “Effective Date”), is entered into by and between Stephen E. Croskrey (“Executive”) and Danimer Scientific, Inc. (the “Company”). Executive and the Company are each referred to herein as a “Party” and together as the “Parties.” Capitalized terms used but undef |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [x] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 13, 2024 |
As filed with the Securities and Exchange Commission on May 13, 2024 As filed with the Securities and Exchange Commission on May 13, 2024 Registration No. |
|
| May 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) DANIMER SCIENTIFIC, INC. |
|
| May 13, 2024 |
Form of Indenture between the Registrant and one or more trustees to be named therein. (2) EX-4.11 2 ea020550601ex4-11danimer.htm FORM OF INDENTURE BETWEEN THE REGISTRANT AND ONE OR MORE TRUSTEES TO BE NAMED THEREIN Exhibit 4.11 DANIMER SCIENTIFIC, INC. AND , TRUSTEE INDENTURE DATED AS OF , 2024 DEBT SECURITIES DANIMER SCIENTIFIC, INC. RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939 AND INDENTURE, DATED AS OF , 2024 Section of Trust Indenture Act of 1939 Section(s) of Indentu |
|
| May 10, 2024 |
Exhibit 10.1 Danimer Scientific Executive Severance and Retention Plan Effective May 9, 2024 ARTICLE 1 NAME, PURPOSE AND EFFECTIVE DATE 1.01. Name and Purpose of Plan. The name of this plan is the Danimer Scientific Executive Severance and Retention Plan (“Plan”). The purpose of the Plan is to assist in retaining certain senior level Eligible Executives of Danimer Scientific, Inc. (the “Company”) |
|
| May 10, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 40 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 8, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 39 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 7, 2024 |
First Quarter 2024 Earnings Presentation May 7, 2024 First Quarter 2024 Earnings Presentation May 7, 2024 This presentation (“Presentation”) is for informational purposes only. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| May 7, 2024 |
Danimer Scientific Announces First Quarter 2024 Results - PHA Revenue Increase of 64% Year-Over-Year – - First Commercial Order Received for 20-Million Pound Cutlery Award - - Previously Announced $20 Million Revolving Credit Facility Provides for Additional Liquidity – - Previously Announced Proposed Pro-Rata Warrant Dividend Transaction - BAINBRIDGE, GA – May 7, 2024 – Danimer Scientific, Inc. |
|
| May 3, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 38 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 3, 2024 |
Danimer Scientific Announces Proposed Pro-Rata Distribution of Warrants to Purchase Common Stock Danimer Scientific Announces Proposed Pro-Rata Distribution of Warrants to Purchase Common Stock Bainbridge, Georgia – May 2, 2024 – Danimer Scientific, Inc. |
|
| April 22, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 37 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| April 22, 2024 |
EXHIBIT 10.1 Execution Version CREDIT AND SECURITY AGREEMENT among Danimer Scientific, Inc., Meredian Holdings Group, Inc., Danimer Scientific Holdings, LLC, Meredian, Inc., Danimer Scientific, L.L.C., Danimer Bioplastics, Inc., Danimer Scientific Kentucky, Inc., (as Borrowers) the other Borrowers and Loan Parties from time to time party hereto, the Lenders from time to time party hereto, AND ABL |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 1, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 36 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| March 29, 2024 |
Danimer Scientific, Inc. Incentive Pay Recovery Policy EXHIBIT 97 DANIMER SCIENTIFIC, INC. INCENTIVE PAY RECOVERY POLICY (Adopted November 8, 2023) Introduction The Board of Directors (the “Board”) of Danimer Scientific, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance com |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39280 DANIMER SCIENTI |
|
| March 29, 2024 |
Subsidiaries of Danimer Scientific Inc. Exhibit 21.1 SUBSIDIARIES OF DANIMER SCIENTIFIC, INC. The following are subsidiaries of Danimer Scientific, Inc. as of December 31, 2023 and the jurisdictions in which they are organized. Company State or Jurisdiction of Incorporation/Organization Meredian Holdings Group, Inc. Delaware Danimer Scientific Holdings, LLC Delaware Danimer Scientific Manufacturing Inc. Delaware Meredian, Inc. Georgia |
|
| March 28, 2024 |
Danimer Scientific Announces Fourth Quarter and Full Year 2023 Results - Results In-Line with March 20 Preannouncement – - Issues FY24 Guidance with Expectation for Accelerating Sales Growth - BAINBRIDGE, GA – March 28, 2024 – Danimer Scientific, Inc. |
|
| March 28, 2024 |
Fourth Quarter 2023 Earnings Presentation March 28, 2024 Fourth Quarter 2023 Earnings Presentation March 28, 2024 This presentation (“Presentation”) is for informational purposes only. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 25, 2024 |
Danimer Scientific Announces $15 Million Registered Direct Offering Exhibit 99.1 Danimer Scientific Announces $15 Million Registered Direct Offering Bainbridge, Georgia – March 20, 2024 – Danimer Scientific, Inc. (NYSE: DNMR) (the “Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that it has entered into a definitive agreement for the purchase and |
|
| March 25, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT March 20, 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Danimer Scientific, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $15,000,000.00 of registered securities of the Comp |
|
| March 25, 2024 |
Exhibit 4.2 COMMON STOCK PURCHASE WARRANT Danimer scientific, inc. Warrant Shares: 15,000,000 Initial Exercise Date: September 25, 2024 Issue Date: March 25, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 25, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 20, 2024, between Danimer Scientific, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| March 25, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Danimer scientific, inc. Warrant Shares: 3,750,000 Initial Exercise Date: March 25, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| March 25, 2024 |
Danimer Scientific Announces Closing of $15 Million Registered Direct Offering Exhibit 99.2 Danimer Scientific Announces Closing of $15 Million Registered Direct Offering Bainbridge, Georgia – March 25, 2024 – Danimer Scientific, Inc. (NYSE: DNMR) (the “Company” or “Danimer Scientific”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced the closing of its previously announced registered direct |
|
| March 22, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration no. 333-267074 Prospectus Supplement (To prospectus dated September 7, 2022) Danimer Scientific, Inc. 11,250,000 Shares of Common Stock Warrants to purchase up to 15,000,000 Shares of Common Stock Pre-Funded Warrants to purchase up to 3,750,000 Shares of Common Stock and Up to 18,750,000 Shares of Common Stock Underlying the Warrants and Pre-Funded War |
|
| March 21, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-267074 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated September 7, 2022) Danimer Scientific, Inc. This prospectus supplement supplements and amends certain information contained in the prospectus supplement dated September 7, 2022 to the prospectus dated as of even date therewith (collectively, the Prospectus”), relating to the offer and sale |
|
| March 20, 2024 |
Danimer Scientific Announces Preliminary Fourth Quarter and Full Year 2023 Results - PHA Revenue Up 11% Year-Over-Year in Fourth Quarter of 2023 - - Previously Announced Cutlery Award Poised to Expand - - PHA Revenue Increase of Approximately 60% Year-Over-Year Expected in First Quarter 2024 - - Expects to Become Adjusted EBITDA Positive in Early 2025 - - Announces Date for Fourth Quarter and Full Year 2023 Earnings Call - BAINBRIDGE, GA – March 20, 2024 – Danimer Scientific, Inc. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 30, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 35 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 18, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 34 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 15, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 33 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| November 14, 2023 |
Danimer Scientific Announces Third Quarter 2023 Results - PHA-Based Product Revenue Grows 58% vs. |
|
| November 14, 2023 |
Third Quarter 2023 Earnings Presentation November 14, 2023 Third Quarter 2023 Earnings Presentation November 14, 2023 This presentation (“Presentation”) is for informational purposes only. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| August 8, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 32 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| August 8, 2023 |
FIRST AMENDMENT TO FINANCING AGREEMENT This FIRST AMENDMENT TO FINANCING AGREEMENT (“Agreement”) dated as of July 20, 2023, is entered into by and among DANIMER SCIENTIFIC, INC. |
|
| August 8, 2023 |
Second Quarter 2023 Earnings Presentation August 8, 2023 Second Quarter 2023 Earnings Presentation August 8, 2023 This presentation (“Presentation”) is for informational purposes only. |
|
| August 8, 2023 |
Danimer Scientific Announces Second Quarter 2023 Results - Issues Separate Release Announcing Accepted Part 2 Application for DoE Loan Guarantee - - Expands Portfolio with Resins for Protective Films, Shrink Wrap & Produce Bags - BAINBRIDGE, GA – August 8, 2023 – Danimer Scientific, Inc. |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2023 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 5, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 31 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 11, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 30 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| May 10, 2023 |
First Quarter 2023 Earnings Presentation May 10, 2023 First Quarter 2023 Earnings Presentation May 10, 2023 This presentation (“Presentation”) is for informational purposes only. |
|
| May 10, 2023 |
Danimer Scientific Announces First Quarter 2023 Results - Cites Improved Visibility into Near-Term Demand - - Reiterates Full Year 2023 Guidance on In-Line Quarterly Results - BAINBRIDGE, GA – May 10, 2023 – Danimer Scientific, Inc. |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [x] Definitive Proxy |
|
| March 29, 2023 |
424B3 1 10-k424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 29 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as suppleme |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39280 DANIMER SCIENTI |
|
| March 28, 2023 |
Fourth Quarter & Full Year 2022 Earnings Presentation March 28, 2023 Fourth Quarter & Full Year 2022 Earnings Presentation March 28, 2023 Disclaimer This presentation (“Presentation”) is for informational purposes only. |
|
| March 28, 2023 |
Subsidiaries of Danimer Scientific Inc. Exhibit 21.1 SUBSIDIARIES OF DANIMER SCIENTIFIC, INC. The following are subsidiaries of Danimer Scientific, Inc. as of December 31, 2022 and the jurisdictions in which they are organized. Company State or Jurisdiction of Incorporation/Organization Meredian Holdings Group, Inc. Delaware Danimer Scientific Holdings, LLC Delaware Danimer Scientific Manufacturing Inc. Delaware Meredian, Inc. Georgia |
|
| March 28, 2023 |
Danimer Scientific Announces Fourth Quarter and Full Year 2022 Results - Results In-Line with March 20 Preannouncement - - Issues FY23 Guidance with Expectation for Accelerating Growth and Margin Improvement - -Kentucky Facility Fully Commissioned and Achieving Throughput and Efficiency Targets - - Announces Submission of Part II Application for DoE Loan Guarantee Program - BAINBRIDGE, GA – March 28, 2023 – Danimer Scientific, Inc. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 20, 2023 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE DANIMER SCIENTIFIC, INC. ) ) C.A. No. 2023-0267-LWW [PROPOSED] FINAL ORDER AND JUDGMENT WHEREAS, this Court having reviewed the Verified Petition for Relief Pursuant to 8 Del. C. § 205 (the “Petition”) filed by petitioner Danimer Scientific Inc., the Court having considered the factors in 8 Del. C. § 205(d), and for good cause having been sho |
|
| March 20, 2023 |
GRANTED IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE DANIMER SCIENTIFIC, INC. |
|
| March 20, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 28 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| March 20, 2023 |
Danimer Scientific Announces Improved Liquidity Position with Closing of $130 Million Senior Secured Term Loan - Pre-announces Preliminary Full Year 2022 Results In-line with Guidance Ranges - - Announces Date for Fourth Quarter and Full Year 2022 Earnings Call - BAINBRIDGE, GA – March 20, 2023 –Danimer Scientific, Inc. |
|
| March 20, 2023 |
Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED WITHOUT COMPLYING WITH THE APPLICABLE PROVISIONS OF THE BYLAWS (AS DEFINED BELOW) AND EXCEPT PURSUANT TO |
|
| March 20, 2023 |
Execution Version Exhibit 10.3 PLEDGE AND SECURITY AGREEMENT dated as of March 17, 2023 between EACH OF THE GRANTORS PARTY HERETO and U.S. Bank Trust Company, National Association, as Collateral Agent 11298/78833-004 CURRENT/129258253v4 03/28/2022 6:01 PM 4887-8092-9621 v2 TABLE OF CONTENTS PAGE Section 1. DEFINITIONS 1 1.1 General Definitions 1 1.2 Definitions; Interpretation 8 Section 2. GRANT O |
|
| March 20, 2023 |
Execution Version Exhibit 10.2 $130,000,000 FINANCING AGREEMENT dated as of March 17, 2023 among DANIMER SCIENTIFIC, INC. as Borrower, THE PERSONS FROM TIME TO TIME PARTY HERETO, as Guarantors, VARIOUS LENDERS FROM TIME TO TIME PARTY HERETO and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Administrative Agent and Collateral Agent TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION |
|
| March 20, 2023 |
Exhibit 10.1 AMENDMENT NO. FIVE TO LOAN AND SECURITY AGREEMENT AND CONSENT This Amendment No. Five to Loan and Security Agreement and Consent (this “Agreement”), dated as of March 16, 2023 (the “Amendment No. Five Effective Date”), is entered into among Danimer Scientific Holdings, LLC, a Delaware limited liability company (“Danimer Holdings”), Meredian Bioplastics, Inc., a Georgia corporation (“M |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 10, 2023 |
424B3 1 section205-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 27 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as s |
|
| March 7, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2023 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 7, 2023 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE DANIMER SCIENTIFIC, INC. ) ) c.a. no. 2023- verified petition for relief pursuant to 8 del. c. § 205 Petitioner Danimer Scientific, Inc. (“Danimer” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a potentially defective corporate act as follows: n |
|
| March 7, 2023 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE DANIMER SCIENTIFIC, INC. ) ) C.A. No. 2023- VERIFIED PETITION FOR RELIEF PURSUANT TO 8 DEL. C. § 205 Petitioner Danimer Scientific, Inc. (“Danimer” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a potentially defective corporate act as follows: N |
|
| February 9, 2023 |
DNMR / Danimer Scientific Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Danimer Scientific Inc. Title of Class of Securities: Common Stock CUSIP Number: 236272100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 8, 2023 |
DNMR / Danimer Scientific Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Danimer Scientific Inc (Name of Issuer) Common Stock (Title of Class of Securities) 236272100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 8, 2022 |
Third Quarter 2022 Earnings Presentation November 8, 2022 Third Quarter 2022 Earnings Presentation November 8, 2022 Disclaimer This presentation (“Presentation”) is for informational purposes only. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q I hope o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| November 8, 2022 |
Danimer Scientific Announces Third Quarter 2022 Results Danimer Scientific Announces Third Quarter 2022 Results BAINBRIDGE, GA – November 8, 2022 – Danimer Scientific, Inc. |
|
| November 8, 2022 |
424B3 1 q3.202210q-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 26 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as s |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 7, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 25 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| September 7, 2022 |
Danimer Scientific, Inc. Common Stock Having an Aggregate Offering Price of Up to $100,000,000 Filed Pursuant to Rule 424(b)(5) Registration No. 333-267074 Prospectus Supplement (To prospectus dated September 7, 2022) Danimer Scientific, Inc. Common Stock Having an Aggregate Offering Price of Up to $100,000,000 This prospectus supplement and the accompanying base prospectus relate to the offer and sale from time to time of shares of Class A common stock, par value $0.0001 per share (?common |
|
| September 7, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction (Commission File Number) ( |
|
| September 7, 2022 |
Exhibit 1.1 Danimer Scientific, Inc. $100,000,000 Class A Common Stock ($0.0001 par value per share) Equity Distribution Agreement September 7, 2022 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York, 10013 Ladies and Gentlemen: Danimer Scientific, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Citigroup G |
|
| September 2, 2022 |
DANIMER SCIENTIFIC, INC. 140 Industrial Boulevard, Bainbridge, GA 39817 (229) 243-7075 CORRESP 1 filename1.htm DANIMER SCIENTIFIC, INC. 140 Industrial Boulevard, Bainbridge, GA 39817 (229) 243-7075 September 2, 2022 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Danimer Scientific, Inc. Registration Statement on Form S-3 Filed: August 25, 2022 File No.: 333-267074 Acceleration Request Ladies and Gentlemen: Pursuant to Rule 461 under the Se |
|
| August 25, 2022 |
Form of Indenture between the Registrant and one or more trustees to be named therein. (2) Exhibit 4.8 DANIMER SCIENTIFIC, INC. AND , TRUSTEE INDENTURE DATED AS OF , 2022 DEBT SECURITIES DANIMER SCIENTIFIC, INC. RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939 AND INDENTURE, DATED AS OF , 2022 Section of Trust Indenture Act of 1939 Section(s) of Indenture ? 310 (a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 ? 311 (a) 613 (b) 613 (c) N |
|
| August 25, 2022 |
As filed with the Securities and Exchange Commission on August 25, 2022 As filed with the Securities and Exchange Commission on August 25, 2022 Registration No. |
|
| August 25, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) DANIMER SCIENTIFIC, INC. |
|
| August 16, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 24 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| August 15, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 9, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 23 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| August 9, 2022 |
Truist Credit Agreement Payoff Confirmation Letter PAYOFF CONFIRMATION LETTER August 5, 2022 Danimer Scientific Holdings, LLC 140 Industrial Boulevard Bainbridge, Georgia 39817 Attention: Stephen E. |
|
| August 9, 2022 |
Second Quarter 2022 Earnings Presentation August 9, 2022 Second Quarter 2022 Earnings Presentation August 9, 2022 Disclaimer This presentation (?Presentation?) is for informational purposes only. |
|
| August 9, 2022 |
Danimer Scientific Announces Second Quarter 2022 Results Danimer Scientific Announces Second Quarter 2022 Results BAINBRIDGE, GA ? August 9, 2022 ? Danimer Scientific, Inc. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| August 1, 2022 |
DANIMER SCIENTIFIC, INC. 140 Industrial Boulevard Bainbridge, GA 39817 August 1, 2022 DANIMER SCIENTIFIC, INC. 140 Industrial Boulevard Bainbridge, GA 39817 August 1, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Ibolya Ignat Li Xiao Re: Danimer Scientific, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 8, 2022 File No. 001-39280 Ladies and Gen |
|
| June 30, 2022 |
DEF 14A 1 2022proxystatement.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential for Use of the Commission Only (as permitted b |
|
| May 11, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 22 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| May 10, 2022 |
Danimer Scientific Announces First Quarter 2022 Results Danimer Scientific Announces First Quarter 2022 Results BAINBRIDGE, GA ? May 10, 2022 ? Danimer Scientific, Inc. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 10, 2022 |
First Quarter 2022 Earnings Presentation May 10, 2022 First Quarter 2022 Earnings Presentation May 10, 2022 Disclaimer This presentation (?Presentation?) is for informational purposes only. |
|
| March 31, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) DANIMER SCIENTIFIC, INC. |
|
| March 31, 2022 |
As filed with the Securities and Exchange Commission on March 31, 2022 As filed with the Securities and Exchange Commission on March 31, 2022 Registration No. |
|
| March 31, 2022 |
Novomer, Inc. 2009 Stock Incentive Plan (1) Exhibit 4.9 NOVOMER, INC. 2009 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2009 Stock Incentive Plan (the ?Plan?) of Novomer, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such p |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39280 DANIMER SCIENTI |
|
| March 8, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 21 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| March 8, 2022 |
Subsidiaries of Danimer Scientific Inc. Exhibit 21.1 SUBSIDIARIES OF DANIMER SCIENTIFIC, INC. The following are subsidiaries of Danimer Scientific, Inc. as of December 31, 2021 and the jurisdictions in which they are organized. ? Company State or Jurisdiction of Incorporation/Organization Meredian Holdings Group, Inc. Delaware Danimer Scientific Holdings, LLC Delaware Danimer Scientific Manufacturing Inc. Delaware Meredian, Inc. Georgia |
|
| March 8, 2022 |
Form of Confirmation for Capped Call Transactions. [] To: Danimer Scientific, Inc. 140 Industrial Boulevard, Bainbridge, GA, 39817 Attention: [] Email: [] Phone: [] From: [] Re: [Base][Additional] Capped Call Transaction Ref. No: [] Date: [], 2021 Dear Ladies and Gentlemen: The purpose of this communication (this ?Confirmation?) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified be |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 10-D ? Form 20-F ? Form N-Cen ? Form 11-K ? Form 10-Q ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? For the Transition |
|
| February 28, 2022 |
Danimer Scientific Announces Preliminary Fourth Quarter and Full Year 2021 Results Exhibit 99.1 Danimer Scientific Announces Preliminary Fourth Quarter and Full Year 2021 Results BAINBRIDGE, GA ? February 28, 2022 ? Danimer Scientific, Inc. (NYSE: DNMR) (?Danimer? or the ?Company?), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today its preliminary financial results for the fourth quarter and full y |
|
| February 28, 2022 |
Exhibit 99.2 Fourth Quarter & Full Year 2021 Earnings Presentation February 28, 2022 Disclaimer This presentation (?Presentation?) is for informational purposes only . This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale woul |
|
| February 28, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2022 |
DNMR / Danimer Scientific Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Danimer Scientific Inc (Name of Issuer) Common Stock (Title of Class of Securities) 236272100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 14, 2022 |
JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| February 9, 2022 |
DNMR / Danimer Scientific Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Danimer Scientific Inc. Title of Class of Securities: Common Stock CUSIP Number: 236272100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| February 3, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction (Commission File Number) (I |
|
| February 3, 2022 |
Exhibit 3.1 sECOND amended and restated BY LAWS OF Danimer Scientific, Inc. (THE ?CORPORATION?) Adopted as of January 28, 2022 ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or indivi |
|
| February 3, 2022 |
424B3 1 ea154934-424b3danimersci.htm PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 20 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated |
|
| January 24, 2022 |
424B3 1 ea154377-424b3danimer.htm PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 19 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated Fe |
|
| January 21, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2022 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction of incorporation) (Commissi |
|
| January 21, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT Employment Agreement, dated as of January 16, 2022, by and between Danimer Scientific, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Michael A. Hajost (?Executive?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). WHEREAS, the Company desires to employ the Executive, and the Executive de |
|
| January 21, 2022 |
Exhibit 99.1 Danimer Scientific Appoints Michael A. Hajost as Chief Financial Officer Jad Dowdy to assume new role of Senior Vice President of Financial Planning and Analysis BAINBRIDGE, Ga. ? Jan. 20, 2022 ? Danimer Scientific, Inc. (NYSE: DNMR) (?Danimer? or the ?Company?), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today a |
|
| December 21, 2021 |
Exhibit 4.1 Execution Version DANIMER SCIENTIFIC, INC. and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of December 21, 2021 3.250% Convertible Senior Notes due 2026 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 12 Section 1.03. Rules of Construction. 13 Article 2. The Notes 13 Section 2.01. Form |
|
| December 21, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| December 21, 2021 |
Form of Confirmation for Capped Call Transactions. Exhibit 10.1 []1 To: Danimer Scientific, Inc. 140 Industrial Boulevard, Bainbridge, GA, 39817 Attention: [] Email: [] Phone: [] From: [] Re: [Base]2[Additional]3 Capped Call Transaction Ref. No: []4 Date: [], 2021 Dear Ladies and Gentlemen: The purpose of this communication (this ?Confirmation?) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade |
|
| December 21, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction of incorporation) (Commiss |
|
| December 20, 2021 |
Submission of Matters to a Vote of Security Holders United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction of incorporation) (Commiss |
|
| December 20, 2021 |
424B3 1 ea152611-424b3danimer.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 |
|
| December 17, 2021 |
Financial Statements and Exhibits, Other Events United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction (Commission File Number) ( |
|
| December 17, 2021 |
Danimer Scientific Prices Upsized $200 Million Convertible Senior Notes Offering Exhibit 99.1 Danimer Scientific Prices Upsized $200 Million Convertible Senior Notes Offering BAINBRIDGE, GA ? December 16, 2021 ? Danimer Scientific, Inc. (NYSE: DNMR) (?Danimer? or the ?Company?), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today the pricing of its offering of $200,000,000 aggregate principal amoun |
|
| December 17, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| December 16, 2021 |
Exhibit 10.4 REAFFIRMATION AND RATIFICATION OF GUARANTORS The undersigned guarantors of the Obligations of Borrowers at any time owing to Lender hereby (i) acknowledge receipt of a copy of the foregoing First Amendment to Revolving Credit Agreement (the ?Agreement?); (ii) consent to Borrowers? execution and delivery thereof and of the other documents, instruments and agreements Borrowers agree to |
|
| December 16, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| December 16, 2021 |
Exhibit 10.2 RATIFICATION BY GUARANTOR The undersigned, Meredian Holdings Group, Inc., a Delaware corporation (?Parent?), hereby states as follows to and for the benefit of Administrative Agent and each Lender, in each case as of the date hereof: (i) acknowledges the execution of the foregoing Amendment No. 4 to Loan and Security Agreement by each Loan Party and of each prior amendment to and cons |
|
| December 16, 2021 |
Exhibit 10.1 AMENDMENT NO. four TO Loan and Security Agreement and consent This Amendment No. Four to Loan and Security Agreement and Consent (this ?Agreement?), dated as of December 15, 2021 (the ?Amendment No. Four Effective Date?), is entered into among Danimer Scientific Holdings, LLC, a Delaware limited liability company (?Danimer Holdings?), Meredian Bioplastics, Inc., a Georgia corporation |
|
| December 16, 2021 |
Exhibit 10.3 FIRST AMENDMENT TO REVOLVING CREDIT AGREEMENT THIS FIRST AMENDMENT TO REVOLVING CREDIT AGREEMENT (this ?Amendment?) is made and entered into this 15th day of December, 2021, by and among by and among Danimer Scientific Holdings, LLC, a Delaware limited liability company (?Holdings?), Meredian, Inc., a Georgia corporation (?Meredian?), Meredian Bioplastics, Inc., a Georgia corporation |
|
| December 16, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction of incorporation) (Commiss |
|
| December 16, 2021 |
Danimer Scientific Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 Danimer Scientific Announces Proposed Convertible Senior Notes Offering BAINBRIDGE, GA ? December 15, 2021 ? Danimer Scientific, Inc. (NYSE: DNMR) (?Danimer? or the ?Company?), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today its intention to offer, subject to market and other conditions, $175,000,000 a |
|
| December 13, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| December 13, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction (Commission File Number) ( |
|
| December 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement |
|
| November 16, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 15, 2021 |
Third Quarter 2021 Earnings Presentation November 15, 2021 Third Quarter 2021 Earnings Presentation November 15, 2021 Disclaimer This presentation (?Presentation?) is for informational purposes only. |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| November 15, 2021 |
Danimer Scientific Announces Third Quarter 2021 Results Danimer Scientific Announces Third Quarter 2021 Results BAINBRIDGE, GA ? November 15, 2021 ? Danimer Scientific, Inc. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement |
|
| October 27, 2021 |
DANIMER SCIENTIFIC, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 DANIMER SCIENTIFIC, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Background On August 11, 2021 (?Closing Date?), Danimer Scientific, Inc., a Delaware corporation (?Danimer?) completed the acquisition of Novomer, Inc., a Delaware Corporation (?Novomer?). Under the terms of the Agreement and Plan of Merger (the ?Merger Agreement?) dated July 28, 2021 and at the Clos |
|
| October 27, 2021 |
Exhibit 99.2 Novomer, Inc. and Subsidiaries Unaudited Condensed Consolidated Financial Statements As of June 30, 2021 and December 31, 2020 and for the six-months ended June 30, 2021 and 2020 Novomer, Inc. and Subsidiaries Unaudited Condensed Consolidated Financial Statements For the Quarterly Period Ended June 30, 2021 Contents Page Unaudited Condensed Consolidated Financial Statements Condensed |
|
| October 27, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| October 27, 2021 |
Convertible Redeemable Preferred Stock Exhibit 99.1 Novomer, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Novomer, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Contents Page Independent Auditors' Report 1-2 Consolidated Financial Statements Consolidated Balance Sheets 3-4 Consolidated Statements of Operations 5 Consolidated Statements of |
|
| October 27, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 17, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| August 16, 2021 |
Letter Agreement, dated August 12, 2021, between the Company and Stuart Pratt Exbibit 10.4 DANIMER SCIENTIFIC, INC. 140 Industrial Boulevard Bainbridge, Georgia 39817 August 12, 2021 Mr. Stuart Pratt 303 Congress Street Boston, Massachusetts 02210 Dear Stuart: Reference is hereby made to the stock option, restricted stock and/or performance stock awards issued to you by Danimer Scientific, Inc. and/or its predecessor entities (collectively, the ?Company?) prior to the date |
|
| August 16, 2021 |
Danimer Scientific, a Next Generation Bioplastics Company, Announces Second Quarter 2021 Results EX-99.1 2 dnmr-20210816ex991.htm EX-99.1 Danimer Scientific, a Next Generation Bioplastics Company, Announces Second Quarter 2021 Results BAINBRIDGE, GA – August 16, 2021 – Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today its financial results for t |
|
| August 16, 2021 |
Second Quarter 2021 Earnings Presentation August 16, 2021 EX-99.2 3 dnmr-20210816ex992.htm EX-99.2 Second Quarter 2021 Earnings Presentation August 16, 2021 Disclaimer This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 3, 2021 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among DANIMER SCIENTIFIC, INC., SUNSHINE MERGER CORP., NOVOMER, INC., AND SHAREHOLDER REPRESENTATIVE SERVICES LLC As Stockholders? Representative July 28, 2021 TABLE OF CONTENTS Article I THE MERGER 2 1.1. The Merger. 2 1.2. General Effects of the Merger. 3 1.3. Effects of the Merger on Securities of Merging Corporations. 3 1.4. Working Capital and C |
|
| August 3, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 DANIMER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-39280 84-1924518 (State or other jurisdiction (Commission File Number) (IRS |
|
| August 3, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| July 30, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| July 29, 2021 |
Exhibit 10.2 DANIMER SCIENTIFIC, INC. 2020 LONG-TERM INCENTIVE PLAN PERFORMANCE STOCK AGREEMENT Danimer Scientific, Inc. (previously known as Live Oak Acquisition Corp., the ?Company?) has granted the Participant (named in Section 1 hereof) a Full Value Award in the form of shares of performance stock (a ?Performance Stock Award?) under the Company?s 2020 Long-Term Incentive Plan (the ?Plan?) with |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 29, 2021 |
Danimer Scientific Novomer Acquisition Update Call July 29, 2021 Danimer Scientific ? Novomer Acquisition Update Call, July 29, 2021 Exhibit 99.1 0 ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only. 1-888-562-0262 1-604-929-1352 www.viavid.com Danimer Sci |
|
| July 29, 2021 |
Exhibit 99.2 Danimer Scientific to Acquire Biodegradable Polymer Producer Novomer Novomer?s Technology and Materials are Highly Compatible with Danimer?s PHA and are Expected to Enable Lower-Cost Biodegradable Products, Benefiting Customers and Creating Value for Shareholders BAINBRIDGE, Ga. ? July 28, 2021 ? Danimer Scientific, Inc. (NYSE: DNMR) (?Danimer? or the ?Company?), a leading next genera |
|
| July 29, 2021 |
Exhibit 10.3 DANIMER SCIENTIFIC, INC. 2020 LONG-TERM INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT Danimer Scientific, Inc. (previously known as Live Oak Acquisition Corp., the ?Company?) has granted the Participant (named in Section 1 hereof) a Non-Qualified Stock Option (the ?Option?) under the Company?s 2020 Long-Term Incentive Plan (the ?Plan?) to purchase that number of shares of Common |
|
| July 29, 2021 |
EX-10.1 2 dnmr-20210729ex101.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT Amended and Restated Employment Agreement, dated as of July 23, 2021, by and between Danimer Scientific, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Stephen E. Croskrey (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “P |
|
| June 16, 2021 |
EX-99.25 2 ruleprovisionnotice.htm NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on June 28, 2021, pursuant to the provisions of Rule 12d2-2 (a). [ X ] 17 CFR 240.12d2-2 |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 10-D ? Form 20-F ? Form N-Cen ? Form 11-K ? Form 10-Q ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? For the Transition Per |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-39280 DANIMER SCIENTIFIC, INC. |
|
| May 18, 2021 |
Danimer Scientific, a Next Generation Bioplastics Company, Announces First Quarter 2021 Results Exhibit 99.1 Danimer Scientific, a Next Generation Bioplastics Company, Announces First Quarter 2021 Results BAINBRIDGE, Ga.-(BUSINESS WIRE)- Danimer Scientific, Inc. (NYSE: DNMR) (?Danimer? or the ?Company?), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today its financial results for the quarter ended March 31, 2021 |
|
| May 18, 2021 |
First Quarter 2021 Earnings Presentation May 17, 2021 EX-99.2 3 dnmr-20210517-ex992.htm EX-99.2 First Quarter 2021 Earnings Presentation May 17, 2021 Disclaimer This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or |
|
| May 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 18, 2021 |
Danimer Scientific, Inc. First Quarter 2021 Earnings Call May 17, 2021 EX-99.1 2 dnmr-20210517-ex991.htm EX-99.1 Danimer Scientific, Inc. – First Quarter 2021 Earnings Call, May 17, 2021 Danimer Scientific, Inc. – First Quarter 2021 Earnings Call, May 17, 2021 Danimer Scientific, Inc. First Quarter 2021 Earnings Call May 17, 2021 C O R P O R A T E P A R T I C I P A N T S Russ Zukowski, Vice President, Corporate Finance Steve Croskrey, Chairman and Chief Executive Off |
|
| May 18, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 DANIMER SCIENTIFIC, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39280 84-1924518 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 17, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 17, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
|
| May 14, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-252515 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated February 16, 2021) Danimer Scientific, Inc. Up to 32,435,961 Shares of Common Stock Up to 16,279,253 Shares of Common Stock Issuable Upon Exercise of Warrants and Options This prospectus supplement supplements the prospectus dated February 16, 2021 (as supplemented or amended from time to |
